SAFETY DATA SHEET

Furosemide Injection Formulation

Section 1: Identification

Product name: Furosemide Injection Formulation

Manufacturer or supplier’s details

Company: MSD
Address: 33 Whakatiki Street - Private Bag 908
         Upper Hutt - New Zealand
Telephone: 908-740-4000
Emergency telephone number: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use

Recommended use: Veterinary product

Section 2: Hazard identification

GHS Classification

Specific target organ toxicity - repeated exposure: STOT RE2 (Kidney, Liver)

GHS label elements

Hazard pictograms: 
Signal word: Warning
Hazard statements: H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.
Precautionary statements: Prevention:
P260 Do not breathe mist or vapours.
Response:
P314 Get medical advice/ attention if you feel unwell.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.
Section 3: Composition/information on ingredients

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>&gt;= 1 -&lt; 10</td>
</tr>
</tbody>
</table>

Section 4: First-aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Nitrogen oxides (NOx)
Carbon oxides
Sulphur oxides
Chlorine compounds

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Section 6: Accidental release measures

**Personal precautions, protective equipment and emergency procedures:**
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

**Environmental precautions:**
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up:**
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

**Technical measures:**
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Local/Total ventilation:**
- Use only with adequate ventilation.

**Advice on safe handling:**
- Avoid inhalation of vapour or mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

**Hygiene measures:**
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
SAFETY DATA SHEET

Furosemide Injection Formulation

Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furosemide</td>
<td>54-31-9</td>
<td>TWA</td>
<td>200 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>OEB 2 (&gt;=100 - 1000 ug/m³)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection

Material: Chemical-resistant gloves

Eye protection: Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance: Aqueous solution

Colour: yellow

Odour: No data available

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available
Section 10: Stability and reactivity

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
<tr>
<td>Possibility of hazardous reactions</td>
<td>Can react with strong oxidizing agents.</td>
</tr>
<tr>
<td>Conditions to avoid</td>
<td>None known.</td>
</tr>
<tr>
<td>Incompatible materials</td>
<td>Oxidizing agents.</td>
</tr>
<tr>
<td>Hazardous decomposition products</td>
<td>No hazardous decomposition products are known.</td>
</tr>
</tbody>
</table>
Section 11: Toxicological information

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Not classified based on available information.

Components:

**Furosemide**:

Acute oral toxicity:
- LD50 (Rat): 2,600 mg/kg
- LD50 (Dog): 2,000 mg/kg
- LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of administration):
- LD0 (Humans): 6 - 29 mg/kg
  Application Route: Intravenous
- LD50 (Rat): 800 mg/kg
  Application Route: Intravenous

Skin corrosion/irritation:
Not classified based on available information.

Serious eye damage/eye irritation:
Not classified based on available information.

Respiratory or skin sensitisation:

Skin sensitisation:
Not classified based on available information.

Respiratory sensitisation:
Not classified based on available information.

Chronic toxicity:

Germ cell mutagenicity:
Not classified based on available information.

Components:

**Furosemide**:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: mouse lymphoma cells
  Result: positive
- Test Type: DNA damage and repair, unscheduled DNA syn-
thesis in mammalian cells (in vitro)
Test system: mammalian liver cells
Result: negative

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells
Test system: Chinese hamster cells
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Chinese hamster
Application Route: Ingestion
Result: negative

Carcinogenicity
Not classified based on available information.

**Components:**

**Furosemide:**
Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks
LOAEL : 16 mg/kg body weight
Result : equivocal

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years
LOAEL : 91 mg/kg body weight
Result : positive

Reproductive toxicity
Not classified based on available information.

**Components:**

**Furosemide:**
Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
General Toxicity - Parent: NOAEL: 90 mg/kg body weight
Result: No effects on reproduction parameters
Test Type: One-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
General Toxicity - Parent: NOAEL: 200 mg/kg body weight
Result: No effects on reproduction parameters

Effects on foetal development:

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 50 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: No embryotoxic effects, No teratogenic effects

Test Type: Fertility/early embryonic development
Species: Mouse
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 25 mg/kg body weight
Developmental Toxicity: NOAEL: 300 mg/kg body weight
Result: Maternal toxicity observed., Fetal effects

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight
Developmental Toxicity: LOAEL: 12.5 mg/kg body weight
Result: Maternal toxicity observed., Reduced number of viable fetuses

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Ingestion
General Toxicity Maternal: LOAEL: 15 mg/kg body weight
Result: Maternal toxicity observed., No effects on foetal development

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

**Furosemide:**
Exposure routes: Ingestion
Target Organs: Kidney
Assessment: Shown to produce significant health effects in animals at concentrations of 10 mg/kg bw or less.

Repeated dose toxicity

Components:

**Furosemide:**
Species: Dog
SAFETY DATA SHEET

Furosemide Injection Formulation

Version: 2.6
Revision Date: 13.09.2019
SDS Number: 632212-00009
Date of last issue: 24.04.2019
Date of first issue: 03.05.2016

NOAEL: 4 mg/kg
LOAEL: 8 mg/kg
Application Route: Ingestion
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Blood disorders
Remarks: Significant toxicity observed in testing

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Furosemide:
Inhalation: Remarks: May be harmful if inhaled.
Skin contact: Remarks: May irritate skin.
Eye contact: Remarks: May cause eye irritation.
Ingestion: Symptoms: Kidney disorders, Headache, electrolyte imbalance, dry mouth, hearing loss, Irregular cardiac activity, Gastrointestinal disturbance, hypotension

Section 12: Ecological information

Ecotoxicity

Components:

Furosemide:
Toxicity to fish: LC50: 500 mg/l
Exposure time: 96 h

Persistence and degradability
No data available

Bioaccumulative potential

Components:

Furosemide:
Partition coefficient: n-octanol/water: log Pow: 2.03

Mobility in soil
No data available

Other adverse effects
No data available

Section 13: Disposal considerations

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging   : Empty containers should be taken to an approved waste handling site for recycling or disposal.
                        If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

NZS 5433
Not regulated as a dangerous good

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number
HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard 2017

HSW Controls
Certified handler certificate not required.
Tracking hazardous substance not required.
Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS            : not determined
DSL             : not determined
IECSC           : not determined

Section 16: Other information

Further information
Sources of key data used to compile the Safety Data Sheet
SAFETY DATA SHEET

Furosemide Injection Formulation

Version 2.6  Revision Date: 13.09.2019  SDS Number: 632212-00009  Date of last issue: 24.04.2019

Date format : dd.mm.yyyy

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; ICAO - International Civil Aviation Organization; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN